US Patent

US7700645 — Pseudopolymorphic forms of a HIV protease inhibitor

Composition of Matter · Assigned to Tibotec Pharmaceuticals Ltd · Expires 2026-12-26 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects new forms of a HIV protease inhibitor and processes for producing them.

USPTO Abstract

New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US7700645
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-12-26
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Tibotec Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.